In Belgium, cost-effectiveness is one of the criteria used by public authorities to assess applications for reimbursement of medicines and Class 1 medical devices, i.e. products for which the applicant claims added therapeutic value and for which a higher price may be charged. For other interventions as well (surgical procedures, vaccines, disease prevention strategies, screening programmes, etc.), economic evaluations and budget impact analyses provide valuable support for the efficient use of limited resources. This guideline is the result of the second update of the KCE guideline on economic evaluations in health and budget impact analyses. The aim is to improve the relevance, methodological quality, transparency and consistency of these economic evaluations of health interventions in Belgium.
Neyt Mattias, Thiry Nancy, Cleemput Irina. Belgian guidelines for economic evaluations and budget impact analyses: third edition. Method. Brussels. Belgian Health Care Knowledge Centre (KCE). 2025. KCE Reports 400C. DOI: 10.57598/R400C.
- the literature review,
- the perspective of the evaluation,
- the target population,
- the comparators,
- the analytic technique,
- the study design,
- the calculation of costs,
- the estimation and valuation of outcomes,
- the time horizon,
- modelling,
- handling uncertainty and testing the robustness of the results,
- the discount rate.
The guidelines for budget impact analysis encompass specificities with respect to the target population and the comparator and refers to guidelines for economic evaluation which should also be respected in the budget impact analysis.
- Scientific report in English (.PDF, 149 p., 2,21 MB)
- Tool EQ-5D Belgian value sets (.XLSM, 832,18 KB)
